Back to search
FDAFDA · Food and drugs·Recall number D-0791-2020

Nizatidine Capsules, USP 150 mg, Rx Only, Mylan Pharmaceuticals Inc., NDC 0378-5150-91.

Published January 29, 2020 · Recall initiated: January 7, 2020

Summary

FDA records drug Class II recall D-0791-2020, published January 29, 2020 and initiated January 7, 2020. Recalling firm: Mylan Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 31,736 bottles of 60 capsules; Lot: Lot Number: 3086746, exp. date May 2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the API Nizatidine.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Mylan Pharmaceuticals Inc.
Distributor
Product was distributed to wholesalers, distributors , retail pharmacies, charitable organizations and mail order pharmacies throughout the United States and the product may have been further distributed.
Lot
Lot Number: 3086746, exp. date May 2020
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Nizatidine Capsules, USP 150 mg, Rx Only, Mylan Pharmaceuticals Inc., NDC 0378-5150-91. recalled?

Yes. FDA published recall D-0791-2020 on January 29, 2020. Reported hazard: CGMP Deviations: Trace amounts of an impurity, N-nitrosodimethylamine (NDMA) was detected in the API Nizatidine.

What should I do if I have this product?

Voluntary: Firm initiated · Letter